UNIVERSITAS
GADJAH MADA
Ekspresi Signal Regulatory Protein Alpha pada Meningioma Orbitokranial
Sarah Rizqia Indrayanti, Prof. Dr. dr. Agus Supartoto Sp.M(K), Dr. dr. Retno Ekantini M.Kes Sp.M(K), dr. Ery Kus Dw
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

1. Apra, C., Peyre, M., & Kalamarides, M. (2018). Current treatment options for meningioma. *Expert Review of Neurotherapeutics*, *18*(3), 241–249. https://doi.org/10.1080/14737175.2018.1429920
2. Apra, C., Roblot, P., Alkhayri, A., le Guérinel, C., Polivka, M., & Chauvet, D. (2020). Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas. *Journal of Neuro-Oncology*, *149*(1), 95–101. https://doi.org/10.1007/s11060-020-03576-8
3. Backer-Grøndahl, T., Moen, B. H., & Torp, S. H. (2012). The histopathological spectrum of human meningiomas. *International Journal of Clinical and Experimental Pathology*, *5*(3), 231–242.
4. Chen, T. T., Brown, E. J., Huang, E. J., & Seaman, W. E. (2004). Expression and Activation of Signal Regulatory Protein α on Astrocytomas. *Cancer Research*, *64*(1), 117–127. https://doi.org/10.1158/0008-5472.CAN-3455-2
5. Choy, W. C., Kim, W., Nagasawa, D., Stramotas, S., Yew, D., Gopen, Q., Parsa, A. T., & Yang, I. C. (2011). The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. *Neurosurgical Focus*, *30*(5). https://doi.org/10.3171/2011.2.FOCUS1116
6. DeMonte, F., W., M. M., & Ossama, A.-M. (2011). Al-Meftys's Meningiomas. In *Angewandte Chemie International Edition, 6(11), 951–952.* (second). Thieme.
7. Deshpande, R. P., Chandra Sekhar, Y. B. V. K., Panigrahi, M., & Babu, P. P. (2017). SIRP Alpha Protein Downregulates in Human Astrocytoma: Presumptive Involvement of Hsa-miR-520d-5p and Hsa-miR-520d-3p. *Molecular Neurobiology*, *54*(10), 8162–8169. https://doi.org/10.1007/s12035-016-0302-8
8. Dizman, N., & Buchbinder, E. I. (2021). *Cancer Therapy Targeting CD47/SIRP α*. *47*, 1–17.
9. Euskirchen, P., & Peyre, M. (2018). Management of meningioma. In *Presse Medicale*. https://doi.org/10.1016/j.lpm.2018.05.016
10. Garzon-Muvdi, T., Bailey, D. D., Pernik, M. N., & Pan, E. (2020). Basis for Immunotherapy for Treatment of Meningiomas. *Frontiers in Neurology*, *11*(August), 1–11. https://doi.org/10.3389/fneur.2020.00945
11. Ghassibi, M. P., Ulloa-Padilla, J. P., & Dubovy, S. R. (2017). Neural tumors of the orbit-what is new? *Asia-Pacific Journal of Ophthalmology*, *6*(3), 273–282. https://doi.org/10.22608/APO.2017157

12. Goldbrunner, R., Minniti, G., Preusser, M., Jenkinson, M. D., Sallabanda, K., Houdart, E., von Deimling, A., Stavrinou, P., Lefranc, F., Lund-Johansen, M., Moyal, E. C. J., Brandsma, D., Henriksson, R., Soffietti, R., & Weller, M. (2016). EANO guidelines for the diagnosis and treatment of meningiomas. In *The Lancet Oncology*. https://doi.org/10.1016/S1470-2045(16)30321-7
13. Gutmann, D. H., & Kettenmann, H. (2019). Microglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology. *Neuron*, *104*(3), 442–449. https://doi.org/10.1016/j.neuron.2019.08.028
14. Hutter, G., Theruvath, J., Graef, C. M., Zhang, M., Schoen, M. K., Manz, E. M., Bennett, M. L., Olson, A., Azad, T. D., Sinha, R., Chan, C., Kahn, S. A., Gholamin, S., Wilson, C., Grant, G., He, J., Weissman, I. L., Mitra, S. S., & Cheshier, S. H. (2019). Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma. *Proceedings of the National Academy of Sciences of the United States of America*, *116*(3), 997–1006. https://doi.org/10.1073/pnas.1721434116
15. Johnson, M. D. (2018). PD-L1 expression in meningiomas. *Journal of Clinical Neuroscience*, *57*, 149–151. https://doi.org/10.1016/j.jocn.2018.08.023
16. Karimi, S., Mansouri, S., Nassiri, F., Bunda, S., Singh, O., Brastianos, P. K., Dunn, I. F., & Zadeh, G. (2021). Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status. *Journal of Neuro-Oncology*, *151*(3), 443–449. https://doi.org/10.1007/s11060-020-03584-8
17. Koga, N., Hu, Q., Sakai, A., Takada, K., Nakanishi, R., Hisamatsu, Y., Ando, K., Kimura, Y., Oki, E., Oda, Y., & Mori, M. (2021). Clinical significance of signal regulatory protein alpha (SIRPα) expression in esophageal squamous cell carcinoma. *Cancer Science*, *112*(8), 3018–3028. https://doi.org/10.1111/cas.14971
18. Magill, S. T., Young, J. S., Chae, R., Aghi, M. K., Theodosopoulos, P. v., & McDermott, M. W. (2018). Relationship between tumor location, size, and WHO grade in meningioma. *Neurosurgical Focus*, *44*(4), 3–8. https://doi.org/10.3171/2018.1.FOCUS17752
19. Maiuri, F., Mariniello, G., Guadagno, E., Barbato, M., Corvino, S., & del Basso De Caro, M. (2019). WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma. *Acta Neurochirurgica*, *161*(12), 2553–2561. https://doi.org/10.1007/s00701-019-04084-z
20. Matozaki, T., Murata, Y., Okazawa, H., & Ohnishi, H. (2009). Functions and molecular mechanisms of the CD47-SIRPα signalling pathway. *Trends in Cell Biology*, *19*(2), 72–80. https://doi.org/10.1016/j.tcb.2008.12.001

21. Murata, Y., Saito, Y., Kotani, T., & Matozaki, T. (2018). CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy. *Cancer Science*, *109*(8), 2349–2357. https://doi.org/10.1111/cas.13663
22. Murata, Y., Tanaka, D., Hazama, D., Yanagita, T., Saito, Y., Kotani, T., Oldenborg, P. A., & Matozaki, T. (2018). Anti-human SIRPα antibody is a new tool for cancer immunotherapy. *Cancer Science*, *109*(5), 1300–1308. https://doi.org/10.1111/cas.13548
23. Ng, H. K., & Chen, L. (1998). Apoptosis is associated with atypical or malignant change in meningiomas. An in situ labelling and immunohistochemical study. *Histopathology*, *33*(1), 64–70. https://doi.org/10.1046/j.1365-2559.1998.00440.x
24. Ogasawara, C., Philbrick, B. D., & Adamson, D. C. (2021). Meningioma: A review of epidemiology, pathology, diagnosis, treatment, and future directions. *Biomedicines*, *9*(3). https://doi.org/10.3390/biomedicines9030319
25. Pant, I., Chaturvedi, S., Sarma, P., & Singh, G. (2021). Histopathological Mapping of Meningiomas: A 10-year Retrospective Analysis. *Indian Journal of Neurosurgery*, *10*(03), 203–209. https://doi.org/10.1055/s-0040-1718990
26. Pinton, L., Solito, S., Masetto, E., Vettore, M., Canè, S., Puppa, A. della, & Mandruzzato, S. (2018). Immunosuppressive activity of tumor-infiltrating myeloid cells in patients with meningioma. *OncoImmunology*, *7*(7), 1–8. https://doi.org/10.1080/2162402X.2018.1440931
27. Supartoto, A., Sasongko, M. B., Respatika, D., Mahayana, I. T., Pawiroranu, S., Kusnanto, H., Sakti, D. H., Nurlaila, P. S., Heriyanto, D. S., & Haryana, S. M. (2019). Relationships between neurofibromatosis-2, progesterone receptor expression, the use of exogenous progesterone, and risk of orbitocranial meningioma in females. *Frontiers in Oncology*, *9*(JAN), 1–7. https://doi.org/10.3389/fonc.2018.00651
28. Takahashi, S. (2018). Molecular functions of SIRPα and its role in cancer (Review). *Biomedical Reports*, *9*(1), 3–7. https://doi.org/10.3892/br.2018.1102
29. Tao, K., Wei, Z., Xia, Y., Zhao, R., & Xu, H. (2022). High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma. *Journal of Healthcare Engineering*, *2022*. https://doi.org/10.1155/2022/3565676
30. Veillette, A., & Chen, J. (2018). SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy. *Trends in Immunology*, *39*(3), 173–184. https://doi.org/10.1016/j.it.2017.12.005

31. Wang, N., & Osswald, M. (2018). Meningiomas: Overview and New Directions in Therapy. *Seminars in Neurology*, *38*(1), 112–120. https://doi.org/10.1055/s-0038-1636502
32. Wiemels, J., Wrensch, M., & Claus, E. B. (2010). Epidemiology and etiology of meningioma. *Journal of Neuro-Oncology*, *99*(3), 307–314. https://doi.org/10.1007/s11060-010-0386-3
33. Willingham, S. B., Volkmer, J. P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., Lovelace, P., Scheeren, F. A., Chao, M. P., Weiskopf, K., Tang, C., Volkmer, A. K., Naik, T. J., Storm, T. A., Mosley, A. R., … Weissman, I. L. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. *Proceedings of the National Academy of Sciences of the United States of America*, *109*(17), 6662–6667. https://doi.org/10.1073/pnas.1121623109
34. Willingham, S. B., Volkmer, J. P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., Lovelace, P., Scheeren, F. A., Chao, M. P., Weiskopf, K., Tang, C., Volkmer, A. K., Naik, T. J., Storm, T. A., Mosley, A. R., … Weissman, I. L. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. *Proceedings of the National Academy of Sciences of the United States of America*, *109*(17), 6662–6667. https://doi.org/10.1073/pnas.1121623109
35. Winn, R. (2017). Youmans & Winn Neurological Surgery. In *Youmans & Winn Neurological Surgery*. https://doi.org/10.1016/j.radonc.2014.12.002
36. Yamasaki, Y., Ito, S., Tsunoda, N., Kokuryo, T., Hara, K., Senga, T., Kannagi, R., Yamamoto, T., Oda, K., Nagino, M., Nimura, Y., & Hamaguchi, M. (2007). SIRPα1 and SIRPα2: Their role as tumor suppressors in breast carcinoma cells. *Biochemical and Biophysical Research Communications*, *361*(1), 7–13. https://doi.org/10.1016/j.bbrc.2007.06.159
37. Yanagita, T., Murata, Y., Tanaka, D., Motegi, S. ichiro, Arai, E., Daniwijaya, E. W., Hazama, D., Washio, K., Saito, Y., Kotani, T., Ohnishi, H., Oldenborg, P. A., Garcia, N. V., Miyasaka, M., Ishikawa, O., Kanai, Y., Komori, T., & Matozaki, T. (2017). Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. *JCI Insight*, *2*(1). https://doi.org/10.1172/jci.insight.89140
38. Yao, C., Li, G., Cai, M., Qian, Y., Wang, L., Xiao, L., Thaiss, F., & Shi, B. (2017). Prostate cancer downregulated SIRP-α modulates apoptosis and proliferation through p38-MAPK/NF-κB/COX-2 signaling. *Oncology Letters*, *13*(6), 4995–5001. https://doi.org/10.3892/ol.2017.6070